strong>Portage Biotech Inc., of Toronto, said subsidiary Biohaven Pharmaceutical Holding Co. Ltd. acquired worldwide intellectual property rights to a portfolio of more than 300 glutamate-modulating prodrugs owned by ALS Biopharma LLC, of Doylestown, Pa., for an undisclosed amount, expanding the company’s plans to develop a portfolio of compounds for diseases where aberrations in glutamate function have been implicated in the pathophysiology of the underlying illness.